صحة وطب

Memorial Sloan Kettering Cancer Center Showcases New Advancements in Cancer Care at Arab Health

Dubai, UAE: January 31st, Memorial Sloan Kettering Cancer Center (MSK), a global leader in cancer treatment, research, and education, participated in Arab Health this year, reaffirming its long-standing commitment to serving patients from the UAE and the broader Middle East region.

 

On this occasion, Dr. Larry Norton, Founding Medical Director of the Evelyn H. Lauder Breast Center at MSK, stated: ““I am delighted to be in the UAE, engaging with colleagues from across the region and around the world. This platform has provided an opportunity to share our latest research and advances in breast cancer management, with a particular focus on estrogen receptor-positive breast cancer, the most prevalent type of breast cancer in the Middle East.

“At MSK, we have made notable advances against breast cancer, including enhancing diagnostic accuracy, improving surgery and radiation therapy, and developing more effective medical treatments as well. We have learned how mutations of the molecules underlying cancer can make cancer cells resistant to hormonal treatment. Effective hormonal therapy has been the mainstay of management for many decades, but cure has been elusive because of the emergence of drug resistance. But there have been significant breakthroughs in recent years by the introduction of medications that can attack the resistance mechanisms and thereby help patients extend the duration of disease control and the duration of their lives.

“Additionally, we have learned how to identify which patients would benefit from particular drugs by examining abnormal DNA in the blood. We are using cancer-killing drugs attached to antibodies to target cancers more specifically. And we are exploring novel approaches to immunotherapy, including freezing the cancer so that it releases molecules that attract cancer-killing white blood cells. By using modern tools like AI and deep machine learning, we are identifying new targets in the cancer so that we can develop new medicines and new combinations.

“These are exciting times. At this meeting I have been honored to interact with researchers and clinicians in the Middle East who are actively studying all aspects of cancer biology and therapy. In particular, I have learned about commitments to AI and genomics that I expect will form the basis for significant further progress. At MSK, we are dedicated to collaborating with our international colleagues, applying and extending the latest tools of laboratory and data science toward ultimate victory over breast and all cancers.”

 

Prof. Dr. Ghassan Abou-Alfa, Gastrointestinal Medical Oncologist at MSK, echoed this sentiment, stating: “We are grateful to be participating at Arab Health this year and would like to extend our gratitude to the UAE Ministry of Health and Prevention for their invitation. At MSK, we take pride in being at the forefront of immunotherapy, a revolutionary approach in cancer care. We recognize that each cancer patient is unique, and our personalized treatment strategies reflect this philosophy. We are always eager to welcome patients to our New York facility and maintain close collaboration with the UAE Ministry of Health and Prevention, Department of Health Abu Dhabi and Dubai Health to explore further partnerships.

“During my keynote address on the final day of Arab Health, I highlighted how the genetic change and environmental impact can influence the outcome of the patient care in the United Arab Emirates and globally. At MSK, we believe in a patient-centered approach to treatment. We say that we do not treat diseases; we treat patients. Every cancer is different, and our commitment lies in tailoring care to the specific needs of each patient, ensuring comprehensive support and care from diagnosis to recovery.”

Reinforcing this commitment to international patient care, Alexandra Forauer, Director of Destination Services at MSK, added: “The Bobst International Center at MSK is introducing enhanced services to improve access to care for patients from outside the U.S. seeking world-class cancer treatment. These enhancements include a more efficient medical record review process, personalized appointment coordination tailored to the individual needs of each patient, and closer collaboration with disease-specific experts to ensure timely and appropriate care. Our goal is to streamline the process so patients traveling to MSK can focus on their health, making the challenges of navigating cancer a little less challenging.”

 

Through these pioneering initiatives and global collaborations, MSK continues to lead the way in advancing cancer care, providing hope and cutting-edge treatment solutions to patients worldwide.

 

 

 

 

عرض المزيد

مقالات ذات صلة

اترك تعليقاً

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *

إغلاق
إغلاق